|
 |
IntegrilinThis page contains recent news articles, when available, and an overview of Integrilin but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Integrilin (when available) Not Available For treatment of myocardial infarction, acute coronary syndrome Mechanism Of Action: Not Available News Articles on Eptifibatide Wrong Blood Thinners for Dialysis Patients Often Given: Study - Dec 11, 2009 Those dialysis patients given Lovenox or Integrilin had a 66% increased chance of in-hospital bleeding and potentially an increased risk of death as well. ... AboutLawsuits.com Misuse Of Blood Thinners In Dialysis Patients Reported - Dec 10, 2009 ...of the American Medical Association that examined the misuse of two blood thinners - Lovenox and Integrilin - in "about 20 percent of kidney dialysis ... Medical News Today (press release) Fulford India Long Term Buy Call: Abhishek Jain, StocksIdea.com - Dec 22, 2009 Dipgenta, Diplene, Dipsalic, Elocon, Emolene, Ensamycin, Ethyol, Garamycin, integrilin, intron MDP, Lotriderm, Netromycin, Polaramine, Quadriderm NF, ... TopNews Accumetrics 以ä¹?观的å‰?景é€?èµ°2009å¹´ - Dec 15, 2009 Integrilin 是å?ƒå¹´åˆ¶è?¯å…¬å?¸(Millennium PharmaceuticaLS) çš„æ³¨å†Œå•†æ ‡ã€‚Plavix 是赛诺è?²-安万特(Sanofi-Aventis) çš„æ³¨å†Œå•†æ ‡ã€‚Effient 是美国礼æ?¥å…¬å?¸(Eli Lilly and ... 凤凰网 Accumetrics 以樂觀的å‰?景é€?èµ°2009å¹´ - Dec 16, 2009 Integrilin 是å?ƒå¹´åˆ¶è—¥å…¬å?¸(Millennium Pharmaceuticals) 的注冊商標。Plavix 是賽諾è?²-安è?¬ç‰¹(Sanofi-Aventis) 的注冊商標。Effient 是美國禮來公å?¸(Eli Lilly and ... 財華網 [AsiaNet]Accumetrics, 2010ë…„ ì „ë§? ê¸?ì •ì ? - Dec 15, 2009 Integrilinì?€ Millennium Pharmaceuticalsì?˜ 등ë¡?ìƒ?í‘œì?´ë‹¤. Plavix는 Sanofi-Aventisì?˜ 등ë¡?ìƒ?í‘œì?´ë‹¤. Effient는 Eli Lilly and Companyì?˜ 등ë¡?ìƒ?í‘œì?´ë‹¤. 매일경제 วิจัยพบหมà¸à¸¡à¸°à¸?ันมัà¸?ง่าย จ่ายยาไม่ดูฉลาà¸? - Dec 11, 2009 ...ผลิตโดยบริษัท ซาโนฟิ-à¸à¹€à¸§à¸™à¸•à¸´à¸ª เà¸à¸ªà¹€à¸ à¸?ับยา “à¸à¸´à¸™à¸•à¸µà¸?ริลินâ€? (Integrilin) หรืà¸à¸—ี่รู้จัà¸?à¸?ันว่า “เà¸à¹‡à¸šà¸•à¸´à¸Ÿà¸´à¸šà¸²à¹„ทด์â€? (eptifibatide) ซึ่งเป็นยาที่ไว้รัà¸?ษาโรคหัวใจ ... ไทยรัฐ 資金調é?”ã€?販売網ã?ªã?©å¢—å¼· ã‚¢ã‚ュメトリクスã?®å¹´é–“æ¥ç¸¾é †èª¿ - Dec 16, 2009 ...インテグリリン(Integrilin)ã?¯ãƒŸãƒ¬ãƒ‹ã‚¢ ム・ファーマスーティカルズ(Millennium Pharmaceuticals)ã?®ç™»éŒ²å•†æ¨™ã€‚プラビックス(Plavix)ã?¯ã‚µãƒŽãƒ•ã‚£ãƒ» ... ファスニングジャーナル Accumetrics cierra el año 2009 con unas previsiones positivas - Dec 15, 2009 El logo de Accumetrics y VerifyNow son marcas registradas de Accumetrics, Inc., ReoPro es una marca registrada de Centocor, Inc., Integrilin es una marca ... Finanzas.com Accumetrics schliesst 2009 mit positivem Ausblick ab - Dec 15, 2009 B. ReoPro(R) und Integrilin(R)) und stellt somit fur den Arzt ein wertvolles Hilfsmittel dar, um sachgerechte Behandlungsentscheidungen treffen zu konnen. ... PR-Inside.com (Pressemitteilung) New approaches to eptifibatide administration - Nov 2, 2009 For ACS, eptifibatide (Integrilin, Schering) is given as an IV bolus of 180 mcg/kg followed by an infusion of 2 mcg/kg per minute until hospital discharge ... Cardiology Today New Management Hires for Burnham Aimed at Accelerating Commercialization Efforts - Oct 22, 2009 Burnham's pipeline includes three drugs that have already won FDA approval — heart attack medicines Integrilin and Aggrastat, and the cancer drug Targretin. ... GenomeWeb Daily News Schering-Plough Reports Financial Results for 2009 Third Quarter - Oct 22, 2009 122 142 (14%) 397 450 (12%) NUVARING 131 118 11% 375 330 14% CLARITIN Rx 95 87 9% 323 326 (1%) AVELOX 70 65 7% 250 274 (9%) INTEGRILIN 74 84 (12%) 223 ... Reuters Millennium deal worth as much as $255.5m.(Millennium Pharmaceuticals ... - Jul 23, 2005 Approved by the Food and Drug Administration in 1998, Integrilin is injected to ... Schering-Plough reported $325 million in Integrilin sales in 2004, ... Free with registration - Boston Globe - AccessMyLibrary.com Millennium Pharma Outlook: 'The Worst Is Over' - Jul 25, 2005 Schering-Plough also plans to purchase existing Integrilin inventories for $45 to $50 million. "We have a neutral opinion of this deal, and Millennium's ... Forbes Less of Schering-Plough clot drug works, safer - Nov 4, 2007 N) sells the drug, eptifibatide, under the brand name Integrilin. ... Schering-Plough reported third-quarter Integrilin sales of $78 million, down 4 percent ... Reuters Millennium Achieves 2005 Financial Guidance - Jan 26, 2006 Effective September 1, 2005, the Company modified the relationship with Schering-Plough for INTEGRILIN from a co-promotion arrangement to a royalty-stream ... biotech-intelligence.com Millennium, Celgene Fall - Jan 10, 2005 Co-promotion revenue from Schering-Plough for its Integrilin injection ... In addition, Integrilin sales were down for the third sequential quarter, ... TheStreet.com - TheStreet.com (subscription) Millennium Pharma Lives Up to Flat Expectations - Jul 26, 2007 This was related to the cardiovascular drug Integrilin supply agreement with Schering-Plough(SGP Quote). US sales, however, increased 6% to $62.6 million ... TheStreet.com - TheStreet.com (subscription) Shift Seen Atop Millennium Pharmaceuticals - Jun 29, 2005 It has two drugs on the market, Integrilin, for acute coronary syndrome, and Velcade, for multiple myeloma. Revenues from drug sales and alliances were $448 ... New York Times Eye On Stocks Eye On Stocks For Thursday, July 28 - Jul 27, 2005 ...agreed to acquire the exclusive developmental and marketing rights of heart drug Integrilin for $35.5 million plus future royalty payments. ... Forbes INTEGRILIN(R) (Eptifibatide) Injection When Added to Clopidogrel … - Mar 1, 2005 CAMBRIDGE, Mass., March 1 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. announced final results from the CLEAR Platelets (Clopidogrel Loading ... RedOrbit Millennium to ax 100 jobs and focus on cancer drugs. - Oct 27, 2005 ...about 1450 in July when Dunsire disclosed her first major initiative, to sell additional rights to Schering-Plough Corp. for the heart drug Integrilin. ... Free with registration - Boston Globe - AccessMyLibrary.com Early Initiation of Integrilin (Eptifibatide) for Heart-Attack... - Nov 14, 2005 DALLAS, TX -- November 14, 2005 -- Schering-Plough Corporation announced that results from the Time to Integrilin Therapy in Acute Myocardial InfarctioN ... DG News Press Release: Robust Sales of Integrilin, ReoPro and Aggrastat Will ... - Sep 9, 2008 Robust Sales of Integrilin, ReoPro and Aggrastat Will Drive the Unstable Angina/Non-ST-Elevation Myocardial Infarction Drug Market. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Millennium Reports Strong Financial Results and Significant … - Jul 27, 2006 Royalties associated with INTEGRILIN(R) (eptifibatide) Injection worldwide sales and VELCADE ex-US sales were $34.2 million for the second quarter 2006. ... Free with registration - PR Newswire - AccessMyLibrary.com The Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved... - Nov 14, 2005 DALLAS, Nov. 14 /PRNewswire-FirstCall/ -- Schering-Plough Corporation and Sinai Center for Thrombosis Research of Baltimore today announced that results ... Free with registration - PR Newswire - AccessMyLibrary.com Press Release: Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin... - Nov 5, 2007 Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary ... Pay-Per-View - PR Newswire - HighBeam Research … to acquire exclusive United States marketing rights for INTEGRILIN... - Aug 1, 2005 Under the new relationship, Schering-Plough will acquire exclusive development and commercialization rights to INTEGRILIN in the United States. ... $4.95 - BIOTECH Patent News - ECNext Millennium Achieves Milestone Payments of Approximately Million - … - Mar 7, 2005 INTEGRILIN is the US market-leading therapy in a class of blood-clot inhibitors known ... INTEGRILIN was launched in the US in 1998 and in Europe in 1999. ... RedOrbit … to Reinforce Benefit of Early Use of INTEGRILIN(R) (eptifibatide)... - Jun 28, 2005 INTEGRILIN will be initiated with the double-bolus dose currently utilized in ... INTEGRILIN is indicated for the treatment of patients with acute coronary ... $4.95 - PR Newswire - ECNext Q4 2004 Millennium Pharmaceuticals Earnings Conference Call - Final. - Jan 27, 2005 Moving on to revenue for our second market leading product, INTEGRILIN. Co-promotion revenue from INTEGRILIN was $47 million for the fourth quarter 2004, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Cilag Holding AG acquires FMS Group NV - Deal Snapshot - AlacraStore.... - Mar 24, 2006 Biotech and its affiliate, Janssen - Cilag, will commercialize Velcade outside of…received Integrilin in this sub - group had a significantly lower ... Pay-Per-View - deals - Alacra Store Press Release: INTEGRILIN(R) (Eptifibatide) Injection When Added to … - Mar 1, 2005 INTEGRILIN(R) (Eptifibatide) Injection When Added to Clopidogrel Provided Superior Platelet Inhibition and Reduced Heart Muscle Death, Based on the Release ... Pay-Per-View - PR Newswire - HighBeam Research … United States marketing rights for INTEGRILIN from Millennium. |... - Aug 1, 2005 Schering-Plough to acquire exclusive United States marketing rights for INTEGRILIN from Millennium. ... find BIOTECH Patent News articles. Pay-Per-View - BIOTECH Patent News - HighBeam Research Q2 2005 Millennium Pharmaceuticals Earnings Conference Call - Final. - Jul 28, 2005 Moving on to INTEGRILIN. US x-factory sales grew to $78 million this quarter, ... Co-promotion revenue of $48 million for INTEGRILIN was down slightly this ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Press Release: Millennium Reports Strong Third Quarter 2005 Financial... - Oct 26, 2005 This result included the one-time sale of INTEGRILIN inventory on September 1, 2005, ... CLEAR Platelets study assessed whether INTEGRILIN can overcome the ... Pay-Per-View - PR Newswire - HighBeam Research … Infarction; Data support clinical benefits of GP IIb-IIIa inhibitor... - Apr 8, 2005 Study results showed that the addition of Integrilin to a commonly used antiplatelet ... Additionally, results supported the vital role of Integrilin in ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Press Release: New Study Will Determine If Comprehensive Anti... - Oct 19, 2005 RESISTOR will determine what happens to these patients when INTEGRILIN is ... CLEAR Platelets study assessed whether INTEGRILIN can overcome the limitations ... Pay-Per-View - PR Newswire - HighBeam Research … Benefits of GP IIb-IIIa Inhibitors and INTEGRILIN(R) (Eptifibatide)... - Mar 8, 2005 In the CLEAR Platelets study, INTEGRILIN, a potent GP IIb-IIIa inhibitor, ... Study results showed that the addition of INTEGRILIN to a commonly used ... RedOrbit Data Support Positive Benefits of GP IIb-IIIa Inhibitors, Integrilin... - Mar 14, 2005 Additionally, results supported the vital role of Integrilin in preventing ... One nonfatal bleeding event in each of the Integrilin groups and one stent ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Press Release: Early Initiation Of INTEGRILIN(R) (Eptifibatide) for... - Nov 12, 2005 Early Initiation Of INTEGRILIN(R) (Eptifibatide) for Heart-Attack Patients in Emergency Department Achieved Superior Coronary Artery Blood Flow. from PR ... Pay-Per-View - PR Newswire - HighBeam Research Integrilin shows 24-hr platelet inhibition.(Brief Article) - Mar 7, 2005 Millennium Pharmaceuticals of the USA has reported encouraging results from a study assessing the efficacy of its drug Integrilin (eptifibatide) in ... $4.95 - Pharma Marketletter - ECNext Riduzione del dosaggio di Integrilin nei pazienti con insufficienza... - Aug 24, 2007 Venerdì 24 Agosto 2007 - GlaxoSmithKline ( GSK ) in accordo con l'EMEA ( European Medicines Agency ) el'AIFA ( Agenzia Italiana del Farmaco ) ha informato i ... XagenaSalute … reported with Millennium's Integrilin.(Millennium Pharmaceuticals... - Mar 21, 2005 A study assessing the efficacy of the glycoprotein IIb-IIIa inhibitor Integrilin (eptifibatide), developed by the US group Millennium Pharmaceuticals, ... $4.95 - Pharma Marketletter - ECNext Integrilin shows 24-hr platelet inhibition.(Brief Article) - Mar 7, 2005 Integrilin was developed by Schering-Plough and is co-promoted by Millennium. Last year, UK drugs major GlaxoSmithKline acquired the European marketing ... Pay-Per-View - Pharma Marketletter - Factiva, from Dow Jones Merger and Acquisition Scenario - Mar 11, 2006 INTEGRILIN is approved for marketing in the United States for the treatment of patients with acute coronary syndromes (ACS), which include unstable angina ... $250.00 - Revere Reports - Revere Millennium and UCB Pharma Enter Into Agreement to Collaborate on Two … - Jan 25, 2005 ...government and third party reimbursement rates; the commercial success of VELCADE and INTEGRILIN; achieving revenue consistent with internal forecasts; ... RedOrbit Merger and Acquisition Scenario - Jan 19, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere EARLY ACS TRIAL OF INTEGRILIN - Jun 30, 2005 Millennium Pharmaceuticals announced publication of the EARLY ACS trial design and rationale in the June 2005 issue of the American Heart Journal. ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Integrilin, Clopidogrel Show Platelet Inhibition, Reduced Heart... - Mar 7, 2005 The study assessed low-to-moderate risk patients and showed that addition of Integrilin, a potent glycoprotein IIb-IIIa inhibitor, to clopidogrel provided ... Pay-Per-View - FDAnews Drug Pipeline Alert - Factiva, from Dow Jones Millennium reduces Q1 loss, boosts revenue - Apr 28, 2005 On the other hand, co-promotion revenue from Integrilin, a heart drug developed jointly by Schering-Plough Corp. (NYSE: SGP) dropped 10 percent to $42.8 ... Boston Business Journal Article: Optimal pediatric clopidogrel dose is found in study.(New & ... - Feb 1, 2007 Platelets showed early and sustained platelet inhibition with INTEGRILIN throughout 24 ... Article: Addition of INTEGRILIN provides superior platelet ... ... Pay-Per-View - Pediatric News - HighBeam Research Hassan engineers a turnaround. - Oct 31, 2005 The firm has acquired exclusive US rights to the cardiovascular drug Integrilin. This was previously co-promoted with Millennium Pharmaceuticals. ... Free with registration - Asia Africa Intelligence Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 12, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Q4 2005 Millennium Pharmaceuticals Earnings Conference Call - Part 1. - Jan 2, 2006 As a reminder, we expect to receive minimum royalties of $85 million from Schering-Plough for INTEGRILIN in both 2006 and 2007. These payments increase the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com POSS TICKER SPAM - Joint efforts producing results for some in the … - Jul 26, 2005 In other healthcare news, the cardiovascular drug INTEGRILIN, the GP IIb-IIIa inhibitor which tops the US market, Schering-Plough Corp. ... $4.95 - M2 Presswire - ECNext New Study Will Determine If Comprehensive Anti-Platelet Therapy Can … - Oct 19, 2005 RESISTOR will determine what happens to these patients when INTEGRILIN is ... By directly preventing the aggregation of platelets, INTEGRILIN produces ... $4.95 - PR Newswire - ECNext Merger and Acquisition Scenario - Feb 9, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere JP Morgan 23rd Annual Healthcare Conference to Webcast Millennium … - Jan 5, 2005 ...co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product ... $4.95 - PR Newswire - ECNext SG Cowen & Co. 25th Annual Healthcare Conference to Webcast … - Mar 10, 2005 ...co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product ... $4.95 - PR Newswire - ECNext Millennium to Participate in the SunTrust Robinson Humphrey 'Off the... - Feb 22, 2005 ...co-promotes INTEGRILIN(R) (eptifibatide) Injection, a market-leading cardiovascular product, and has a robust clinical development pipeline of product ... $4.95 - PR Newswire - ECNext Merger and Acquisition Scenario - Jan 26, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Product Licensing; Biopharmaceutical co. achieves milestone payments ... - Apr 4, 2005 INTEGRILIN is the US market-leading therapy in a class of blood-clot inhibitors known ... INTEGRILIN was launched in the US in 1998 and in Europe in 1999. ... Pay-Per-View - Pharma Business Week - Factiva, from Dow Jones Millennium Pharmaceuticals Inc - Jun 19, 2006 COR's Integrilin was approved by the FDA in 1998 to treat acute coronary syndrome ... Integrilin had been co-promoted in the U.S. with Schering-Plough. ... $35.00 - Stock Reports - Standard & Poor's Merger and Acquisition Scenario - Apr 7, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere … to Reinforce Benefit of Early Use of INTEGRILIN(R) (eptifibatide)... - Jun 28, 2005 INTEGRILIN will be initiated with the double-bolus dose currently utilized in the cardiac ... Platelets study, INTEGRILIN, a potent GP IIb-IIIa inhibitor, ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - Dec 15, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere New Jersey Supreme Court, Equity and Law Reports - BENDER v. … - Jul 19, 2006 Q: Doctor, do you know how Integrilin works on platelets? A: Well, in a very broad sense, but I'm not an expert at that. I'm not a hematologist and do not ... Pay-Per-View - New Jersey Supreme Court, Equity and... - Loislaw Heart Disease; Pharmaceutical company announces final results from … - Mar 21, 2005 ..."The CLEAR Platelets study assessed whether INTEGRILIN can overcome the limitations ... Both INTEGRILIN treatment regimens demonstrated significantly lower ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Heart Disease; Pharmaceutical company announces final results from … - Mar 27, 2005 ..."The CLEAR Platelets study assessed whether INTEGRILIN can overcome the limitations ... Both INTEGRILIN treatment regimens demonstrated significantly lower ... Pay-Per-View - Heart Disease Weekly - Factiva, from Dow Jones Millennium Pharmaceuticals, Inc. Pharmaceutical company announces … - Mar 23, 2005 ..."The CLEAR Platelets study assessed whether INTEGRILIN can overcome the limitations ... Both INTEGRILIN treatment regimens demonstrated significantly lower ... Pay-Per-View - Biotech Week - Factiva, from Dow Jones Heart Disease; Pharmaceutical company announces final results from … - Mar 21, 2005 ..."The CLEAR Platelets study assessed whether INTEGRILIN can overcome the limitations ... Both INTEGRILIN treatment regimens demonstrated significantly lower ... Pay-Per-View - Biotech Business Week - Factiva, from Dow Jones Merger and Acquisition Scenario - Jun 16, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Event Brief of Q1 2006 Millennium Pharmaceuticals Earnings Conference... - Apr 27, 2006 This decrease was primarily the result of lower net reimbursement received from Schering-Plough for INTEGRILIN. 2. Effective 09/01/05, MLNM modified its ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Oct 27, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 27, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere … ; EARLY ACS trial designed to reinforce benefit of early use of... - Jul 26, 2005 Integrilin will be initiated with the double-bolus dose currently utilized in the cardiac catheterization lab in order for investigators to further evaluate ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Analyst Day 2005 - Part 3. - Nov 2, 2005 If we turn to the cost of sales, if we look in there we see Velcade cost of sales, we see Integrilin cost of sales on an ongoing basis. ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Article: Glaxo 'downplayed' warning on heart-attack risk from Aids... - May 12, 2008 INTEGRILIN in Europe and will enhance the GSK cardiovascular critical care portfolio ... heart muscle, which in turn, can lead to heart attacks. ... Pay-Per-View - Independent - London - HighBeam Research New Anti-Clotting Drug Shows Promise in Heart Patients - Nov 4, 2007 Another trial found that Integrilin (eptifibatide) was as effective as ReoPro ... Finally, a fourth study found that giving Integrilin for a shorter period ... Washington Post New York: Väntas öppna kring noll - Jul 25, 2005 ...läkemedelsbolaget Millennium Pharmaceuticals med 4,2 procent efter beskedet att Schering-Plough skaffat en exklusiv marketing licens för Integrilin. ... Affärsvärlden - Affärsvärlden Event Brief of Q1 2006 MEDICINES CO Earnings Conference Call - Part 1... - Apr 19, 2006 In comparison MDCO calls it an Integrilin presentation in the same time frame with 66%. 10. On avg., the survey physicians reported a mean of less than one ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Aug 25, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Press Release: Millennium to Highlight 2004 Accomplishments and 2005 ... - Jan 10, 2005 INTEGRILIN demand sales are estimated to be $355 million as reported by a ... INTEGRILIN(R) (eptifibatide) Injection: Early Acute Coronary Syndrome (ACS) ... Pay-Per-View - PR Newswire - HighBeam Research … the Positive Clinical Benefits of GP IIb-IIIa Inhibitors and INTEGR... - Mar 8, 2005 In the CLEAR Platelets study, INTEGRILIN, a potent GP IIb-IIIa inhibitor, ... Increased use of gpIIb/IIIa inhibitor therapies such as Integrilin ... Pay-Per-View - PR Newswire - HighBeam Research Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Event Brief of Q2 2006 Millennium Pharmaceuticals Earnings Conference... - Jul 27, 2006 Royalties associated with INTEGRILIN worldwide sales and VELCADE ex-US sales were ... s relationship with Schering-Plough for INTEGRILIN, along with other ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Millennium Bids $515 Mln for Anormed: Tops Genzyme - Sep 26, 2006 The company has an agreement with Johnson & Johnson to market the Velcade cancer medicine, and earns royalties from Schering-Plough Corp. for its Integrilin ... Bloomberg Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Article: Syrians turn over Saddam half brother Al-Hassan thought to... - Feb 28, 2005 BIOTECH Patent News; August 1, 2005 ; 700+ words ... ... promoting INTEGRILIN in the United States and sharing profits ... and royalties over the United ... Pay-Per-View - Chicago Sun-Times - HighBeam Research Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Medicure Inc. at BIO CEO & Investor Conference 2007 - Part 1. - Feb 13, 2007 AGGRASTAT sells at about $500 a patient, INTEGRILIN at 7 to $900, and ReoPro at $1300. So it is the lowest cost, has efficacy, safety benefits, ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Ace, Netflix, American Express - MarketWatch - Jul 24, 2005 Schering-Plough Corp. has agreed to acquire the exclusive US marketing rights for cardiovascular drug Integrilin from its collaboration partner, ... MarketWatch Competitors by Product Report - May 17, 2008 Products:. Integrilin (Eptifibatide Injection) ... Integrilin (Eptifibatide). Angina. Anticoagulating Agents. Platelet Aggregation Inhibitors ... $75.00 - Revere - Alacra Store Merger and Acquisition Scenario - May 13, 2006 Integrilin (Eptifibatide); MLN1202 (Anti-MCP1/CCR2 Antibody); MLN2222/CAB-2 (Complement ... Integrilin (Eptifibatide). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Sep 2, 2006 Integrilin (Eptifibatide); MLN1202 (Anti-MCP1/CCR2 Antibody); MLN2222/CAB-2 (Complement ... Integrilin (Eptifibatide). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Millennium Sees Loss Below $100 Million - Jan 10, 2005 Millennium has two products on the market -- Integrilin, which helps prevent occlusion of the ... Millennium's partner form Integrilin is Schering-Plough. ... TheStreet.com - TheStreet.com (subscription) Big Pharma Turns A Corner - Aug 1, 2005 ..."We think the transfer of US rights for Integrilin to Schering-Plough (nyse: SGP - news - people ) is long-term strategic positive," it said. ... Forbes Eye On Stocks Eye On Stocks For Monday, July 25 - Jul 22, 2005 This could occur if Millennium became serious about cost reductions, were to divest Integrilin or add a drug for hematological malignancies to ride shotgun ... Forbes Merger and Acquisition Scenario - Aug 19, 2006 Integrilin (Eptifibatide); MLN2222/CAB-2 (Complement Inhibitor); MLN1202 (Anti-MCP1/CCR2 ... Integrilin (Eptifibatide). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 27, 2007 Integrilin (Eptifibatide); MLN1202 (Anti-MCP1/CCR2 Antibody); Velcade (Bortezomib) ... Integrilin (Eptifibatide). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - May 5, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Oct 20, 2007 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal Antibody) ... Integrilin (Eptifibatide Injection). Angina. Anticoagulating Agents ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Apr 12, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Article: Saddam's half-brother, wanted as insurgent leader, captured... - Feb 27, 2005 BIOTECH Patent News; August 1, 2005 ; 700+ words ... ... promoting INTEGRILIN in the United States and sharing profits ... and royalties over the United ... Pay-Per-View - AP Worldstream - HighBeam Research Article: Suicide Bomber Kills at Least 106 in Iraq - AP Online |... - Feb 28, 2005 BIOTECH Patent News; August 1, 2005 ; 700+ words ... ... promoting INTEGRILIN in the United States and sharing profits ... and royalties over the United ... Pay-Per-View - AP Online - HighBeam Research Merger and Acquisition Scenario - May 17, 2008 Integrilin (Eptifibatide Injection); MLN1202 (Anti-MCP1/CCR2 Monoclonal ... Integrilin (Eptifibatide Injection). Phase I/Phase II Clinical Stage Products ... $250.00 - Revere Reports - Revere Brand Names/Synonyms: Integrilin is also known by the following brand names and/or synonymsIntegrilin; Integrilin (Millennium Pharm) Drug Category: Integrilin is categorized under the following by the FDA: Anticoagulants; Antiplatelet Agents; unclassified therapeutic agents (92:00.00) Dosage Forms: SOLUTION Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: N 6 -(aminoiminomethyl)-N 2 -(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L -prolyl-L-cysteinamide |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |